Deferred Revenue (Details)	1 Months Ended					0 Months Ended	1 Months Ended			12 Months Ended
	Sep. 30, 2012	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2013 Qsymia USD ($)	Dec. 31, 2013 Upfront payments Qsymia USD ($)	Jul. 05, 2013 License and commercialization agreement SPEDRA Menarini Group	Oct. 31, 2013 License and commercialization agreement SPEDRA Menarini Group EUR (€)	Dec. 31, 2013 License and commercialization agreement SPEDRA Menarini Group USD ($)	Dec. 31, 2013 License and commercialization agreement SPEDRA Menarini Group EUR (€)	Dec. 31, 2013 License and commercialization agreement STENDRA or SPEDRA Auxilium Pharmaceuticals, Inc. USD ($)	Dec. 31, 2013 License and commercialization agreement Royalties SPEDRA Menarini Group EUR (€)	Dec. 31, 2013 License and commercialization agreement Royalties SPEDRA Menarini Group USD ($)
DEFERRED REVENUE
Current deferred revenue		$ 17,255,000	$ 1,150,000	$ 10,300,000	$ 10,300,000			$ 10,600,000	€ 8,000,000	$ 6,700,000	€ 8,000,000	$ 10,600,000
Non-Current deferred revenue		10,360,000						10,600,000	8,000,000	6,700,000
Prepayment received for future royalties							6,700,000				6,700,000
Prepayment received for future royalties before withholding tax							€ 8,000,000				€ 8,000,000
Reimbursable withholding tax rate (as a percent)						16.00%	16.00%				16.00%
Qsymia shelf life period	36 months									48 months